biostudies-literatureUnknown26(1)Kumano M<h4>Background</h4>Drug-induced acute interstitial nephritis (DI-AIN) is the most common type of AIN. DI-AIN occurs when medications trigger a T cell-mediated immune response that promotes tubulitis and interstitial inflammation with eosinophils, often resulting in acute kidney injury (AKI) with nephromegaly. Recently, prolonged use of cyclin-dependent kinase (CDK) 4/6 inhibitors, as oral molecular-targeted drugs for breast cancer, was identified as a cause of AKI, including AIN and acute tubular necrosis (ATN). To date, there have been no reported cases of AIN associated with the use of abemaciclib, a CDK4/6 inhibitor.<h4>Case presentation</h4>A 66-year-old Japanese woman presented with persistent diarrhea and nausea shortly after the initiation of abemaciclib for breast cancer and was suBMC nephrology543https://www.ebi.ac.uk/biostudies/studies/S-EPMC12482685biostudies-literatureAbemaciclib-associated acute interstitial nephritis successfully treated with glucocorticoids: a case report and literature review.PMC12482685Kumano MYanagidani HYoshida MTeragawa YMaeoka YTakahashi AMasaki TfalseAbemaciclib-associated acute interstitial nephritis successfully treated with glucocorticoids: a case report and literature review.<h4>Background</h4>Drug-induced acute interstitial nephritis (DI-AIN) is the most common type of AIN. DI-AIN occurs when medications trigger a T cell-mediated immune response that promotes tubulitis and interstitial inflammation with eosinophils, often resulting in acute kidney injury (AKI) with nephromegaly. Recently, prolonged use of cyclin-dependent kinase (CDK) 4/6 inhibitors, as oral molecular-targeted drugs for breast cancer, was identified as a cause of AKI, including AIN and acute tubular necrosis (ATN). To date, there have been no reported cases of AIN associated with the use of abemaciclib, a CDK4/6 inhibitor.<h4>Case presentation</h4>A 66-year-old Japanese woman presented with persistent diarrhea and nausea shortly after the initiation of abemaciclib for breast cancer and was su2025-01-01T00:00:00Z2025 Sep2026-06-04T00:17:47.588Z2026-05-03T03:12:16.159ZS-EPMC124826854102387310.1186/s12882-025-04442-3